播放中国国产国语纯一级黄片免费看, 大鸡吧快来啊阿啊阿啊黄片在线播放, 中文精品日韩网站在线观看视频免费, 别揉我奶头~嗯~啊~一区二区三区,AV无码播放一级毛片免费古装,亚洲春色一区二区三区,91大神极品,美国一级大黄一片免费下载,午夜爽爽爽男女免费观看软件

Welcome to LookChem.com Sign In|Join Free

CAS

  • or
2-[(6-Chloro-3,4-dihydro-3-Methyl-2,4-dioxo-1(2h)-pyriMidinyl)Methyl]benzonitrile is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

865758-96-9

Post Buying Request

865758-96-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

865758-96-9 Usage

Chemical Properties

White Solid

Check Digit Verification of cas no

The CAS Registry Mumber 865758-96-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,5,7,5 and 8 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 865758-96:
(8*8)+(7*6)+(6*5)+(5*7)+(4*5)+(3*8)+(2*9)+(1*6)=239
239 % 10 = 9
So 865758-96-9 is a valid CAS Registry Number.

865758-96-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-((6-Chloro-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile

1.2 Other means of identification

Product number -
Other names 2-[(6-chloro-3-methyl-2,4-dioxopyrimidin-1-yl)methyl]benzonitrile

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:865758-96-9 SDS

865758-96-9Synthetic route

3-methyl-6-chlorouracil
4318-56-3

3-methyl-6-chlorouracil

2-(bromomethyl)benzonitrile
22115-41-9

2-(bromomethyl)benzonitrile

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile
865758-96-9

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile

Conditions
ConditionsYield
Stage #1: 3-methyl-6-chlorouracil With N-ethyl-N,N-diisopropylamine In tetrahydrofuran at 23℃; for 0.25h; Schlenk technique; Inert atmosphere;
Stage #2: 2-(bromomethyl)benzonitrile In tetrahydrofuran at 65℃; for 2h; Schlenk technique; Inert atmosphere;
96%
With 1-methyl-pyrrolidin-2-one; N-ethyl-N,N-diisopropylamine at 60 - 65℃; for 3h; Large scale;96.42%
With N-ethyl-N,N-diisopropylamine In dichloromethane at 40 - 45℃; Solvent; Temperature;95.8%
3-methyl-6-chlorouracil
4318-56-3

3-methyl-6-chlorouracil

2-cyanobenzyl chloride
612-13-5

2-cyanobenzyl chloride

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile
865758-96-9

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In dimethyl sulfoxide at 60℃; for 1h;85.62%
With potassium carbonate; potassium iodide In N,N-dimethyl acetamide at 50 - 100℃;
2-[(6-chloro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)methyl]benzonitrile
865758-95-8

2-[(6-chloro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)methyl]benzonitrile

dimethyl sulfate
77-78-1

dimethyl sulfate

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile
865758-96-9

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile

Conditions
ConditionsYield
Stage #1: 2-[(6-chloro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)methyl]benzonitrile With potassium carbonate In N,N-dimethyl-formamide at 25℃; for 0.25h;
Stage #2: dimethyl sulfate In N,N-dimethyl-formamide for 12h; Solvent; Reagent/catalyst;
84.78%
2-[(6-chloro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)methyl]benzonitrile
865758-95-8

2-[(6-chloro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)methyl]benzonitrile

methyl iodide
74-88-4

methyl iodide

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile
865758-96-9

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile

Conditions
ConditionsYield
Stage #1: 2-[(6-chloro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)methyl]benzonitrile With sodium hydride; lithium bromide In tetrahydrofuran; N,N-dimethyl-formamide at 20℃; for 0.333333h;
Stage #2: methyl iodide In tetrahydrofuran; N,N-dimethyl-formamide at 0 - 35℃; Further stages.;
72%
Stage #1: 2-[(6-chloro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)methyl]benzonitrile With sodium hydride; lithium bromide In tetrahydrofuran; N,N-dimethyl-formamide at 0 - 20℃; Inert atmosphere;
Stage #2: methyl iodide In tetrahydrofuran; N,N-dimethyl-formamide at 20 - 35℃; Inert atmosphere;
72%
Stage #1: 2-[(6-chloro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)methyl]benzonitrile With sodium hydride; lithium bromide In N,N-dimethyl-formamide at 0℃; for 0.5h; Inert atmosphere;
Stage #2: methyl iodide In N,N-dimethyl-formamide at 80℃; Inert atmosphere;
70%
methyl iodide
74-88-4

methyl iodide

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile
865758-96-9

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile

Conditions
ConditionsYield
Stage #1: 2-[(6-chloro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)methyl]benzonitrile With sodium hydride; lithium bromide In tetrahydrofuran; DMF (N,N-dimethyl-formamide) at 0 - 20℃; for 0.333333h;
Stage #2: methyl iodide In tetrahydrofuran; DMF (N,N-dimethyl-formamide) at 20 - 35℃;
72%
Stage #1: 2-[(6-chloro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)methyl]benzonitrile With sodium hydride; lithium bromide In tetrahydrofuran; N,N-dimethyl-formamide at 20℃; for 0.333333h;
Stage #2: methyl iodide In tetrahydrofuran; N,N-dimethyl-formamide at 20 - 35℃;
72%
1-(2-cyanobenzyl)-3-methylpyrimidine-2,4,6(1H,3H,5H)-trione
1246610-72-9

1-(2-cyanobenzyl)-3-methylpyrimidine-2,4,6(1H,3H,5H)-trione

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile
865758-96-9

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile

Conditions
ConditionsYield
With phosphorus pentachloride; N-benzyl-N,N,N-triethylammonium chloride; trichlorophosphate In acetonitrile for 4 - 5h; Product distribution / selectivity; Reflux;70.5%
1-(2-cyanobenzyl)-3-methylpyrimidine-2,4,6(1H,3H,5H)-trione
1246610-72-9

1-(2-cyanobenzyl)-3-methylpyrimidine-2,4,6(1H,3H,5H)-trione

A

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile
865758-96-9

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile

B

C13H10ClN3O2

C13H10ClN3O2

Conditions
ConditionsYield
Stage #1: 1-(2-cyanobenzyl)-3-methylpyrimidine-2,4,6(1H,3H,5H)-trione With trichlorophosphate at 0℃;
Stage #2: With water at 0 - 110℃;
A 37%
B n/a
2-(bromomethyl)benzonitrile
22115-41-9

2-(bromomethyl)benzonitrile

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile
865758-96-9

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: NaH / dimethylformamide; dimethylsulfoxide / 0.5 h / 0 °C
1.2: LiBr / dimethylformamide; 1,2-dimethoxy-ethane / 0.25 h / 0 - 20 °C
1.3: 54 percent / dimethylformamide; dimethylsulfoxide / 0 - 20 °C
2.1: NaH; LiBr / dimethylformamide; tetrahydrofuran / 0.33 h / 20 °C
2.2: 72 percent / dimethylformamide; tetrahydrofuran / 0 - 35 °C
View Scheme
Multi-step reaction with 2 steps
1.1: sodium hydride / dimethyl sulfoxide; N,N-dimethyl-formamide; mineral oil / 0.5 h / 0 °C / Inert atmosphere
1.2: 0.25 h / 0 °C / Inert atmosphere
1.3: 0 - 20 °C / Inert atmosphere
2.1: sodium hydride; lithium bromide / tetrahydrofuran; N,N-dimethyl-formamide; mineral oil / 0.33 h / 20 °C / Inert atmosphere
2.2: 20 - 35 °C / Inert atmosphere
View Scheme
Multi-step reaction with 2 steps
1: N-ethyl-N,N-diisopropylamine / 1-methyl-pyrrolidin-2-one; toluene / 70 - 80 °C
2: potassium carbonate / acetone / 50 - 60 °C
View Scheme
1-methyl-2,4,6-pyrimidinetrione
2565-47-1

1-methyl-2,4,6-pyrimidinetrione

2-(bromomethyl)benzonitrile
22115-41-9

2-(bromomethyl)benzonitrile

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile
865758-96-9

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile

Conditions
ConditionsYield
Stage #1: 1-methyl-2,4,6-pyrimidinetrione With N,N-dimethyl-aniline; trichlorophosphate In toluene at 90 - 95℃; for 2h;
Stage #2: 2-(bromomethyl)benzonitrile With N-ethyl-N,N-diisopropylamine In tetrahydrofuran at 60 - 65℃; Temperature; Concentration;
40 g
(R)-piperidin-3-ylcarbamic acid tert-butyl ester
309956-78-3

(R)-piperidin-3-ylcarbamic acid tert-butyl ester

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile
865758-96-9

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile

2-[[6-[(3R)-3-tert-butoxycarbonylamino-1-piperidinyl]-3,4-dihydro-2,4-dioxo-3-methyl-1(2H)-pyrimidinyl]methyl]benzonitrile
1246610-74-1

2-[[6-[(3R)-3-tert-butoxycarbonylamino-1-piperidinyl]-3,4-dihydro-2,4-dioxo-3-methyl-1(2H)-pyrimidinyl]methyl]benzonitrile

Conditions
ConditionsYield
With potassium carbonate In N,N-dimethyl-formamide at 75℃; for 6h; Product distribution / selectivity;96%
With potassium carbonate at 80 - 90℃;90%
With tetrabutylammomium bromide; potassium carbonate; sodium iodide In acetonitrile for 25h; Reflux;89.3%
3-(R)-aminopiperidine dihydrochloride

3-(R)-aminopiperidine dihydrochloride

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile
865758-96-9

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile

Alogliptin hydrochloride
1246610-75-2

Alogliptin hydrochloride

Conditions
ConditionsYield
Stage #1: 3-(R)-aminopiperidine dihydrochloride; 2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile With potassium carbonate In water; isopropyl alcohol at 75 - 80℃; Large scale;
Stage #2: With hydrogenchloride In chloroform; water at -5 - 0℃; for 2h; Reagent/catalyst; Large scale;
95.1%
Stage #1: 3-(R)-aminopiperidine dihydrochloride; 2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile In water; isopropyl alcohol at 60 - 65℃; Inert atmosphere;
Stage #2: With potassium carbonate In water; isopropyl alcohol at 60 - 65℃; Inert atmosphere;
Stage #3: With hydrogenchloride In tetrahydrofuran; water; isopropyl alcohol at 0 - 15℃; Inert atmosphere;
2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile
865758-96-9

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile

(R)-piperidine-3-carboxamide p-toluenesulfonate

(R)-piperidine-3-carboxamide p-toluenesulfonate

(R)-1-(3-(2-cyanobenzyl)-1-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)piperidine-3-carboxamide

(R)-1-(3-(2-cyanobenzyl)-1-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)piperidine-3-carboxamide

Conditions
ConditionsYield
With potassium carbonate In water; isopropyl alcohol at 65℃; for 23h;95%
With potassium carbonate In water; isopropyl alcohol at 70℃; for 18h; Temperature;93%
2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile
865758-96-9

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile

C18H21N5O2

C18H21N5O2

C31H30N8O4

C31H30N8O4

Conditions
ConditionsYield
With potassium carbonate In N,N-dimethyl-formamide at 65℃; for 5h; Temperature;93%
3-(R)-aminopiperidine dihydrochloride

3-(R)-aminopiperidine dihydrochloride

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile
865758-96-9

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile

alogliptin
850649-61-5

alogliptin

Conditions
ConditionsYield
With potassium hydrogencarbonate In isopropyl alcohol; acetonitrile at 60℃; for 6h;92.7%
With triethylamine In isopropyl alcohol at 65℃; for 17h;85%
With tetra-n-butylphosphonium chloride; sodium hydrogencarbonate In water; toluene at 60 - 70℃; Solvent; Temperature;85.7%
2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile
865758-96-9

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile

benzyl N-[(3R)-3-piperidyl]carbamate
478646-32-1

benzyl N-[(3R)-3-piperidyl]carbamate

benzyl N-[(3R)-1-{3-[(2-cyanophenyl)methyl]-1-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl}piperidin-3-yl]carbamate

benzyl N-[(3R)-1-{3-[(2-cyanophenyl)methyl]-1-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl}piperidin-3-yl]carbamate

Conditions
ConditionsYield
With potassium carbonate In N,N-dimethyl-formamide at 60℃; for 8h; Solvent;92.7%
With cetyltrimethylammonim bromide; potassium carbonate In acetone for 24h; Solvent; Reagent/catalyst; Reflux;87.7%
(R)-piperidin-3-ylcarbamic acid tert-butyl ester
309956-78-3

(R)-piperidin-3-ylcarbamic acid tert-butyl ester

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile
865758-96-9

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile

alogliptin
850649-61-5

alogliptin

Conditions
ConditionsYield
Stage #1: 2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile With (1,3,5-triaza-7-phosphaadamantan-1-ium-1-yl)butane-1-sulfonate; palladium diacetate In N,N-dimethyl-formamide for 0.0833333h; Schlenk technique; Inert atmosphere;
Stage #2: (R)-piperidin-3-ylcarbamic acid tert-butyl ester With triethylamine In N,N-dimethyl-formamide at 23℃; for 2h; Schlenk technique; Inert atmosphere;
Stage #3: With trifluoroacetic acid In dichloromethane; N,N-dimethyl-formamide at 23℃; for 1h; Schlenk technique; Inert atmosphere;
92%
2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile
865758-96-9

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile

(3R)-3-aminopyrrolidine dihydrochloride
103831-11-4, 116183-81-4, 116183-83-6, 122458-34-8

(3R)-3-aminopyrrolidine dihydrochloride

(R)-6-(3-aminopyrrolidin-1-yl)-1-(2-cyanobenzyl)-3-methylpyrimidine-2,4(1H,3H)-dione

(R)-6-(3-aminopyrrolidin-1-yl)-1-(2-cyanobenzyl)-3-methylpyrimidine-2,4(1H,3H)-dione

Conditions
ConditionsYield
With sodium hydrogencarbonate In isopropyl alcohol at 100℃; for 2h; Molecular sieve;84%
2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile
865758-96-9

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile

(S)-3-aminopyrrolidine dihydrochloride
103831-11-4, 116183-81-4, 116183-83-6, 122458-34-8

(S)-3-aminopyrrolidine dihydrochloride

(S)-6-(3-aminopyrrolidin-1-yl)-1-(2-cyanobenzyl)-3-methylpyrimidine-2,4(1H,3H)-dione

(S)-6-(3-aminopyrrolidin-1-yl)-1-(2-cyanobenzyl)-3-methylpyrimidine-2,4(1H,3H)-dione

Conditions
ConditionsYield
With sodium hydrogencarbonate In isopropyl alcohol at 100℃; for 2h; Molecular sieve;82%
2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile
865758-96-9

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile

(R)-5-azaspiro[2.4]heptan-7-amine dihydrochloride

(R)-5-azaspiro[2.4]heptan-7-amine dihydrochloride

(R)-6-(7-amino-5-azaspiro[2.4]heptan-5-yl)-1-(2-cyanobenzyl)-3-methylpyrimidine-2,4(1H,3H)-dione

(R)-6-(7-amino-5-azaspiro[2.4]heptan-5-yl)-1-(2-cyanobenzyl)-3-methylpyrimidine-2,4(1H,3H)-dione

Conditions
ConditionsYield
With sodium hydrogencarbonate In isopropyl alcohol at 100℃; for 2h; Molecular sieve;81%
2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile
865758-96-9

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile

ethylenediamine
107-15-3

ethylenediamine

C15H17N5O2

C15H17N5O2

Conditions
ConditionsYield
With triethylamine In tetrahydrofuran for 4h; Reflux;80%
tert-butyl (3R)3-aminopiperidine-1-carboxylate
188111-79-7

tert-butyl (3R)3-aminopiperidine-1-carboxylate

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile
865758-96-9

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile

C23H29N5O4

C23H29N5O4

Conditions
ConditionsYield
With sodium carbonate In isopropyl alcohol for 13h; Time; Reflux;78%
2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile
865758-96-9

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile

1-methyl-1-propanethiol
513-53-1

1-methyl-1-propanethiol

2-((6-(sec-butylthio)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile

2-((6-(sec-butylthio)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile

Conditions
ConditionsYield
Stage #1: 2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile With (1,3,5-triaza-7-phosphaadamantan-1-ium-1-yl)butane-1-sulfonate; palladium diacetate In N,N-dimethyl-formamide for 0.0833333h; Schlenk technique; Inert atmosphere;
Stage #2: 1-methyl-1-propanethiol With potassium phosphate In N,N-dimethyl-formamide at 50℃; for 2h; Schlenk technique; Inert atmosphere;
76%
2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile
865758-96-9

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile

thiophenol
108-98-5

thiophenol

2-((3-methyl-2,4-dioxo-6-(phenylthio)-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile

2-((3-methyl-2,4-dioxo-6-(phenylthio)-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile

Conditions
ConditionsYield
Stage #1: 2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile With (1,3,5-triaza-7-phosphaadamantan-1-ium-1-yl)butane-1-sulfonate; palladium diacetate In N,N-dimethyl-formamide for 0.0833333h; Schlenk technique; Inert atmosphere;
Stage #2: thiophenol With potassium phosphate In N,N-dimethyl-formamide at 50℃; for 2h; Schlenk technique; Inert atmosphere;
72%
2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile
865758-96-9

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile

(R)-3-piperidinyl phthalimide hydrochloride

(R)-3-piperidinyl phthalimide hydrochloride

alogliptin
850649-61-5

alogliptin

Conditions
ConditionsYield
Stage #1: 2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile; 3-(R)-piperidinyl phthalimide hydrochloride With sodium hydrogencarbonate In methanol at 100℃; for 0.75h;
Stage #2: With methanol; hydrazine hydrate for 4h; Reagent/catalyst; Temperature; Reflux; Further stages;
70%
2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile
865758-96-9

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile

C13H9Cl2N3O2

C13H9Cl2N3O2

Conditions
ConditionsYield
With N-chloro-succinimide In 1,2-dichloro-ethane at 80℃; for 8h; Solvent; Temperature;65.8%
2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile
865758-96-9

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile

3-(R)-aminopiperidine dihydrochloride
943528-10-7

3-(R)-aminopiperidine dihydrochloride

trifluoroacetic acid
76-05-1

trifluoroacetic acid

2-{6-[3(R)-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl}benzonitrile trifluoroacetate

2-{6-[3(R)-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl}benzonitrile trifluoroacetate

Conditions
ConditionsYield
Stage #1: 2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile; 3-(R)-aminopiperidine dihydrochloride With sodium hydrogencarbonate In methanol at 100℃; for 2h; Molecular sieve;
Stage #2: trifluoroacetic acid
56%
2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile
865758-96-9

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile

DL-3-aminohexahydro-1H-azepin
69154-03-6

DL-3-aminohexahydro-1H-azepin

trifluoroacetic acid
76-05-1

trifluoroacetic acid

A

2-{6-[(+/-)-3-aminoazepan-1-yl]-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl}benzonitrile trifluoroacetate

2-{6-[(+/-)-3-aminoazepan-1-yl]-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl}benzonitrile trifluoroacetate

B

2-{6-[(+/-)-azepan-3-ylamino]-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl}benzonitrile trifluoroacetate

2-{6-[(+/-)-azepan-3-ylamino]-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl}benzonitrile trifluoroacetate

Conditions
ConditionsYield
Stage #1: 2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile; DL-3-aminohexahydro-1H-azepin With sodium hydrogencarbonate In methanol at 100℃; Molecular sieve;
Stage #2: trifluoroacetic acid
A 50%
B 11%
3-(R)-aminopiperidine dihydrochloride

3-(R)-aminopiperidine dihydrochloride

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile
865758-96-9

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile

2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]benzonitrile hydrochloride

2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]benzonitrile hydrochloride

Conditions
ConditionsYield
Stage #1: 3-(R)-aminopiperidine dihydrochloride; 2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile With triethylamine In water; isopropyl alcohol at 65℃; for 48h;
Stage #2: With hydrogenchloride In ethanol
47.53%
In water; isopropyl alcohol at 58 - 68℃;
With sodium carbonate; potassium iodide In isopropyl alcohol at 65 - 70℃;40 g
2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile
865758-96-9

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile

tert-butyl alcohol
75-65-0

tert-butyl alcohol

C17H19N3O3

C17H19N3O3

Conditions
ConditionsYield
With sodium hydrogencarbonate In water at 70℃; for 12h;44%
2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile
865758-96-9

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile

(5-azaspiro[2.5]oct-8-yl)carbamic acid tert-butyl ester
1232542-24-3

(5-azaspiro[2.5]oct-8-yl)carbamic acid tert-butyl ester

tert-butyl 5-(3-(2-cyanobenzyl)-1-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)5-azaspiro[2.5]octan-8-ylcarbamate
1232542-25-4

tert-butyl 5-(3-(2-cyanobenzyl)-1-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)5-azaspiro[2.5]octan-8-ylcarbamate

Conditions
ConditionsYield
With sodium hydrogencarbonate In dimethyl sulfoxide at 100℃; for 2h; Inert atmosphere;40%
2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile
865758-96-9

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile

ethanol
64-17-5

ethanol

C15H15N3O3

C15H15N3O3

Conditions
ConditionsYield
With sodium hydrogencarbonate In water at 73℃; for 8h;34.5%
2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile
865758-96-9

2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)methyl)benzonitrile

isopropyl alcohol
67-63-0

isopropyl alcohol

C16H17N3O3

C16H17N3O3

Conditions
ConditionsYield
With sodium hydrogencarbonate In water at 68℃; for 16h;23%

865758-96-9Relevant articles and documents

Synthesis process of alogliptin benzoate

-

Paragraph 0007; 0092; 0121-0144, (2021/02/10)

The invention discloses a synthesis process of alogliptin benzoate. The synthesis process comprises the following steps: 1, preparing an initial raw material 6-chlorouracil; 2, preparing 2-((6-chlorine-2, 4-dioxo-3, 4-dihydro-2H-pyrimidine-1-radical)methyl)cyanophenyl; 3, preparing 2-[(6-chlorine-3, 4-dihydro-3-methyl-2, 4-dioxo-1(2H)-pyrimidinyl)methyl]benzonitrile; 4, preparing alogliptin; 5, preparing alogliptin benzoate. According to the invention, the alogliptin benzoate is synthesized by taking cheap and easily available 6-chlorouracil, alpha bromo-o-methylbenzonitrile and (R)-3-aminopiperidine as raw materials through reactions such as alkylation, methylation, affinity substitution, salification and the like; according to the synthetic route, raw materials are cheap and easy to obtain, the synthetic cost is reduced, all steps are classic reactions, and synthesis improvement is easy; the improved process is low in raw material cost, simple to operate, mild in reaction condition,simple in post-treatment and suitable for industrial production.

Preparation method of alogliptin benzoate intermediate and preparation method of alogliptin benzoate

-

Paragraph 0074-0079; 0092-0095, (2021/08/28)

The invention provides a reparation method of an alogliptin benzoate intermediate and a preparation method of alogliptin benzoate. The yield of the alogliptin benzoate intermediate prepared by the method is not lower than 88%, and the purity is not lower than 99.5%; and according to the alogliptin benzoate raw material medicine prepared by the method, D90 does not exceed 220 microns, and preferably does not exceed 200 microns. All indexes of the prepared pharmaceutical composition meet medicinal requirements, the quality is stable in the storage process, and the clinical curative effect and medication safety can be guaranteed.

3, 4-dihydropyrimidine benzonitrile derivative as well as preparation method and application thereof

-

Paragraph 0026-0027; 0065, (2021/03/13)

The invention provides a 3, 4-dihydropyrimidine benzonitrile derivative as well as a preparation method and application thereof. The invention discloses a structure of a specific impurity (RRT is an impurity of 1.22) generated in the process of preparing alogliptin benzoate by adopting the route of the original research patent for the first time. The series of impurities have a warning structure,and the content of the impurities in the alogliptin benzoate finished product needs to be detected according to related limits of the genetically toxic impurities. The invention further provides a preparation and purification method of the high-purity compound shown in the formula (A) and a detection method of the content of the impurity compound in the alogliptin benzoate medicine, and thereforequality control over the alogliptin benzoate medicine is achieved.

Preparation method of alogliptin benzoate

-

Paragraph 0028-0029; 0033-0034, (2021/01/29)

The invention discloses a preparation method of alogliptin benzoate. Main starting materials of the preparation method are 6-chloro-3-methyluracil, o-cyanobenzyl bromide, (R)-3-Boc-aminopiperidine andbenzoic acid. According to the method, all indexes meet the specification, meanwhile, dangerous reagents such as sodium hydride and highly toxic methyl iodide are prevented from being used in the reaction process, the requirement for the operation process is not strict, and water-free and oxygen-free conditions are not needed; a high-boiling-point mixed solvent is not used in the reaction, and the solvent is easy to recycle; the selected starting materials are available in the market and easy to obtain, and large-scale production is facilitated; in addition, starting materials or intermediates in the synthetic route are good in stability and convenient to store and control, and genotoxic impurities are avoided in the reaction process; and the synthesis process is environment-friendly.

Novel preparation process of alogliptin benzoate

-

Paragraph 0027; 0038-0040; 0047-0048; 0049-0050; 0051-0052, (2021/05/08)

The invention discloses a novel preparation process of alogliptin benzoate. The method comprises the steps: reacting 3-methyl-6-chlorouracil serving as an initial raw material with 2-cyanobenzyl bromide under an alkaline condition by taking toluene as a solvent to obtain 2-[(6-chloro-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl)methyl]benzonitrile, then reacting the solvent system with (R)-3-Boc-aminopiperidine under an alkaline condition, dissociating a protecting group by using acid to obtain alogliptin, and carrying out salifying reaction on the alogliptin and benzoic acid to finally prepare the alogliptin benzoate which is an anti-type 2 diabetes medicine. The preparation method adopts a one-pot method, has the advantages of low raw material cost, high yield, reduction of post-treatment operation of each chemical reaction in multi-step reaction, great shortening of the production period, few impurities generated in the reaction, high product quality, relative reduction of the use amount of chemical reagents, relatively environmental protection and the like, and is beneficial to industrial production.

Refining method of alogliptin benzoate

-

Paragraph 0116-0118, (2021/06/06)

The invention discloses a refining method of alogliptin benzoate, which is characterized in that an alogliptin benzoate crude product (the purity is 99.73%) is used as a starting raw material, the alogliptin benzoate crude product is dissolved by adding an organic solvent, and is cooled to crystallize to obtain a high-purity target product alogliptin benzoate solid, and the purity of the alogliptin benzoate solid can reach 99.99% through HPLC detection. Compared with the prior art, the toxicity of the used solvent is low, the mother liquor solvent can be recycled, and the environmental pollution is small; and the operation is simple and feasible, and industrial large-scale production is facilitated.

Industrial production method of Alogliptin benzoate

-

Paragraph 0049-0066; 0106-0120; 0155-0169, (2019/02/04)

The invention relates to an industrial production method of Alogliptin benzoate, and belongs to the technical field of industrial pharmacy. The method comprises three steps of 1, preparing an Alogliptin intermediate AG I; 2, preparing an Alogliptin intermediate AG II; 3, preparing the Alogliptin benzoate. The industrial production method has the beneficial effects that the reaction conditions areproper; the operation is simple and convenient; the realization is easy; only the Alogliptin intermediate AG II is prepared; then, the AG II and benzoic acid are subjected to tetrahydrofuran synthesis; the Alogliptin benzoate can be obtained; the process is saved; the cost is reduced; used solvents have small environment pollution; the operation is safe; under the large-scale industrial productioncondition, the existing average yield is only about 30 percent; under the condition that the final yield reaches 19.32kg, the finial product yield reaches 94.77 percent; the total yield reaches 60.11percent; high quality and purity can be maintained; the production efficiency is greatly improved.

Pd/PTABS: Catalyst for Room Temperature Amination of Heteroarenes

Murthy Bandaru, Siva Sankar,Bhilare, Shatrughn,Chrysochos, Nicolas,Gayakhe, Vijay,Trentin, Ivan,Schulzke, Carola,Kapdi, Anant R.

supporting information, p. 473 - 476 (2018/01/28)

A mild and highly efficient catalytic amination procedure for chloroheteroarenes at ambient temperature using the Pd/PTABS catalytic system is reported. The protocol is selective for the amination of chloroheteroarenes using secondary amines such as piperidine, pyrrolidine, and several others. The exceptional mildness of the developed protocol is beneficial for the synthesis of a crucial Buparlisib intermediate as well as the formal synthesis of Alogliptin in competitive yields.

Preparation method of alogliptin benzoate

-

Paragraph 0042; 0043; 0051, (2018/05/16)

The invention discloses a preparation method of alogliptin benzoate. The preparation method of alogliptin benzoate comprises the following steps of, firstly, reacting 3-methyl-6-chlorouracil with 2-cyanobenzyl bromide to obtain 2-(6-chloro-3-methyl-2, 4-dioxo-3, 4-dihydro-2H-pyrimidine-1-methyl)-benzonitrile; secondly, reacting 2-(6-chloro-3-methyl-2, 4-dioxo-3, 4-dihydro-2H-pyrimidine-1-methyl)-benzonitrile with (R)-3-aminoperidine dihydrochloride to obtain alogliptin; thirdly, salifying alogliptin with benzoic acid to obtain alogliptin benzoate. According to the preparation method of alogliptin benzoate, condensation reaction in the first step is implemented in dichloromethane solvent and under reflux conditions, thereby being mild in conditions and capable of achieving a yield higher than 90%; condensation reaction in the second step is implement in water or water-methylbenzene mixed solution to avoid production of disubstituted impurities and achieving high product purity.

Preparation method of alogliptin benzoate impurity

-

Paragraph 027; 0028, (2018/04/01)

The invention relates to a preparation method of alogliptin benzoate impurity and belongs to the technical field of pharmaceutical chemicals. The preparation method of alogliptin benzoate impurity provided by the invention comprises the following steps: (1) preparing TM1 2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)cyanophenyl by taking 6-chloro-3-methylpyrimidin-2,4(1H,3H)-diketone as a raw material which reacts with 2-bromomethyl cyanophenyl; (2) preparing alogliptin benzoate impurity BP1 through a reaction between the TM1 and monohydric alcohol in an alkaline condition, wherein the structural formula of the BP1 is shown in the description. The preparation method provided by the invention is convenient to operate, the reaction conditions are mild and controllable,the side reactions are reduced, and therefore, the target product alogliptin benzoate is easy to separate and purify and has high purity.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 865758-96-9